No previous suggestions found.

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Immunovant

#2974

Rank

$4.25B

Marketcap

US United States

Country

Immunovant
Leadership team

Dr. Frank M. Torti M.B.A., M.D., MBA (Exec. Chairperson of the Board)

Dr. Peter Salzmann M.B.A., M.D. (CEO & Director)

Ms. Eva Renee Barnett M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Pharmaceutical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2018
Company Registration
SEC CIK number: 0001764013
Traded as
IMVT
Social Media
URL
https://immunovant.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
History

Immunovant was founded in July 2016 with a focus on leveraging the power of FcRn biology to develop innovative therapies for autoimmune diseases. In June 2017, the company entered into a partnership with Genentech, which granted the company access to a portfolio of FcRn-targeting antibodies from three distinct classes. In September 2018, Immunovant entered into a collaboration with AbbVie. Through this partnership, Immunovant acquired exclusive rights to develop and commercialize certain AbbVie products for the treatment of certain autoimmune diseases.

Mission
Our mission is to develop innovative therapies to improve the lives of patients suffering from autoimmune diseases and other disorders.
Vision
At Immunovant, our vision is to be a trusted partner in autoimmune disease research, discovery and development and to deliver our therapies with the highest standards of quality and innovation.
Key Team

Dr. William L. Macias M.D., Ph.D. (Chief Medical Officer)

Dr. Julia G. Butchko Ph.D. (Chief Devel. & Technology Officer)

Dr. Chau Cheng M.B.A., Ph.D. (VP of Investor Relations)

Mr. Mark S. Levine (Chief Legal Officer & Corp. Sec.)

Ms. Lauren Schrier M.B.A. (VP of Marketing)

Recognition and Awards
Immunovant has received several awards, including a 2018 Paul G. Allen Frontiers Group Award, a 2017 Boston Business Journal Life Sciences Awards and a 2016 LIFE Prize Award in recognition of the company's innovative approach to treating autoimmune diseases.
References

https://in.investing.com/equities/immunovant-inc

https://finance.yahoo.com/quote/IMVT/profile?p=IMVT

https://www.crunchbase.com/organization/immunovant

https://sec.report/CIK/0001764013

https://companiesmarketcap.com/

https://immunovant.com

Immunovant
Leadership team

Dr. Frank M. Torti M.B.A., M.D., MBA (Exec. Chairperson of the Board)

Dr. Peter Salzmann M.B.A., M.D. (CEO & Director)

Ms. Eva Renee Barnett M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Pharmaceutical
Number of Employees
100 - 500
Headquarters
New York, New York, United States
Established
2018
Company Registration
SEC CIK number: 0001764013
Traded as
IMVT
Social Media
URL
https://immunovant.com
About

Businessabc provides a digital business directory, resources, a marketplace, and a digital blockchain AI certification for businesses, organisations, and professionals.

contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy